
2800 Plymouth Rd, NCRC Bldg 16, Room 115W
Ann Arbor, MI 48109-2800
Available to mentor

Brent K. Hollenbeck, MD, MS, is a practicing urologic oncologist and has been on faculty at the University of Michigan since 2005. A graduate of the Indiana University School of Medicine, Dr. Hollenbeck completed his residency in urology and fellowship in oncology at Michigan. Dr. Hollenbeck has served as Urology Chair at Massachusetts General Hospital and Walter S. Kerr, Jr. Professor of Surgery in the Field of Urology and Professor of Surgery at Harvard Medical School.
His clinical interest and expertise have uniformly focused on caring for men with prostate cancer. Over the past two decades, he has built one of the largest prostate cancer surgical practices in the state of Michigan, receiving referrals from patients and colleagues from around the U.S.
Dr. Hollenbeck’s research examines how delivery system organization and incentives embedded within payment models affect clinical practice and quality, particularly with respect to prostate cancer. He is PI of 5 active R01 grants (AHRQ, 3 NCI, NIA) and 1 Research Scholar Grant from the American Cancer Society. Three awards (RSGI-21-097-01-HOPS, R01 CA275993, R01 CA279746) examine the effects of financial incentives (commercial prices, ownership of pharmacies, urology practice consolidation) on prostate cancer quality. One (R01 CA269367) represents a clinically translational focus aimed at leveraging our understanding of financial incentives to design and implement an advanced alternative payment model—one that aligns payment with quality—for newly diagnosed prostate cancer. The last two (R01 AG068074, R01 HS028975) are more broadly focused and evaluate effects of payment reform and delivery system innovation on quality.
-
FellowshipUniversity of Michigan–Ann Arbor, Urology, 2005
-
FellowshipUniversity of Michigan–Ann Arbor, Urology, 2004
-
Chief ResidentUniversity of Michigan–Ann Arbor, Urology, 2003
-
ResidencyUniversity of Michigan–Ann Arbor, Urology, 2002
-
IntershipUniversity of Michigan–Ann Arbor, Ann Arbor, 1998
Dr. Hollenbeck's research examines how delivery system organization and incentives affect clinical practice. He has been generously supported by both career development and research scholar grants from the American Cancer Society. His ongoing research agenda is supported by numerous extramural agencies, including R01 funding from the Agency for Healthcare Research and Quality and the National Institute on Aging. Dr. Hollenbeck has written extensively on financial incentives, quality, and cost and their intersection with evolving delivery system reforms. Dovetailing with his research, Dr. Hollenbeck is deeply committed to mentoring young physicians who share his passion for clinical investigation and health services research. He has served as primary mentor for more than a dozen postdoctoral trainees, nearly all of who have successfully competed for extramural funding after finishing their training. Dr. Hollenbeck has been integrally involved as co-investigator for the "first-of-its-kind" NIDDK T32 award aimed at training urologists in health services research. He is co-principal investigator of a T32 award supporting the scientific development of urologic oncologists, sponsored by the NCI.
-
Srivastava A, Kaufman SR, Liu X, Maganty A, Shay A, Oerline M, Dall C, Faraj KS, Guro P, Hill D, Nguyen T, Herrel LA, Hollenbeck BK, Shahinian VB. Cancer Medicine, 2025 Mar 1; 14 (6):Journal ArticleSpillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer
DOI:10.1002/cam4.70796 PMID: 40111071 -
Maganty A, Kaufman SR, Oerline MK, Faraj K, Caram MEV, Ryan AM, Shahinian VB, Hollenbeck BK. Urology, 2025 Feb 1; 196: 137 - 144.Journal ArticleCommercial Prices and Care for Medicare Beneficiaries With Prostate Cancer
DOI:10.1016/j.urology.2024.11.009 PMID: 39581508 -
Morgan TM, Daignault-Newton S, Spratt DE, Dunn RL, Singhal U, Okoth LA, Feng FY, Johnson AM, Lane BR, Linsell S, Ghani KR, Montie JE, Mehra R, Hollenbeck BK, Maatman T, Wojno K, Burks FN, Bekong D, Curry J, Rodriguez P, Kleer E, Sarle R, Miller DC, Cher ML. European Urology, 2025 Feb 1; 87 (2): 228 - 237.Journal ArticleImpact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial
DOI:10.1016/j.eururo.2024.09.011 PMID: 39379238 -
Srivastava A, Kaufman SR, Shay A, Oerline M, Liu X, Van Til M, Linsell S, Labardee C, Dall C, Faraj KS, Maganty A, Borza T, Ginsburg K, Hollenbeck BK, Shahinian VB. JAMA Network Open, 2025 Jan 8; 8 (1):Journal ArticlePhysician Payment Incentives and Active Surveillance in Low-Risk Prostate Cancer
DOI:10.1001/jamanetworkopen.2024.53658 PMID: 39775806 -
Srivastava A, Liu X, Maganty A, Kaufman SR, Shay A, Oerline M, Dall C, Faraj KS, Ryan AM, Hollenbeck BK, Shahinian VB. Cancer, 2025 Jan 1; 131 (1):Journal ArticleCommercial prices and their influence on urology practices: Prostate cancer care among men with Medicare
DOI:10.1002/cncr.35633 PMID: 39501423 -
Ying M, Shay A, Hollingsworth JM, Shahinian VB, Hollenbeck BK. Health Services Research, 2025 Jan 1;Journal ArticleEarly Effects of Pathways to Success on Utilization in Traditional Medicare
DOI:10.1111/1475-6773.14597 -
Faraj KS, Kaufman SR, Oerline M, Dall C, Srivastava A, Caram MEV, Shahinian VB, Hollenbeck BK. Cancer Medicine, 2025 Jan 1; 14 (1):Journal ArticleThe 340B Drug Pricing Program and Management of Advanced Prostate Cancer
DOI:10.1002/cam4.70552 PMID: 39739625 -
Dall CP, Liu X, Faraj KS, Srivastava A, Kaufman SR, Hartman N, Shahinian VB, Hollenbeck BK. Cancer Medicine, 2024 Dec 1; 13 (23):Journal ArticleHospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery
DOI:10.1002/cam4.70436 PMID: 39624952